Organic Active Ingredients TRIZ Cases

Administering dihydronicotinamide riboside with a purine nucleoside phosphorylase inhibitor restores NAD levels, reducing cartilage degradation.

Spray drying aqueous solutions of 21-disodium phosphate pregnane derivatives minimizes compound degradation during solid isolation.

Pyrazine derivatives inhibit URAT1, addressing limited therapeutic options for hyperuricemia and gout.

Pyrazolopyrimidinone compounds inhibit PDE5 with nanomolar potency, minimizing adverse effects from nonspecific inhibition of other isoforms.

Imidazo[1,2-a]pyridine-2-carboxamides enhance receptor affinity to treat diseases linked to insufficient Nurr-1 activity.

Measuring CSK and PAK2 levels predicts clinical outcomes for ER+ breast cancer patients undergoing treatment.

Targeting overexpressed TLR4 on mesenchymal stromal cells reduces growth support for myeloma cells, addressing chemoresistance in multiple myeloma.

A crosslink multivalent binding model predicts optimal ligand valency for targeted drug particles based on receptor expression levels.

Chitosan nanoparticles deliver intestinal programmed death ligand 1 polypeptides to modulate T cell responses and reduce graft-versus-host disease severity.

Antiseptic solution maintains chemical stability during storage via pH adjustment, then activates antimicrobial efficacy upon application.

Segmented extended release tablets stabilize plasma concentrations, eliminating deep fluctuations from twice-daily dosing.

Pentablock copolymer micelles encapsulate mRNA and zwitterionic agents via electrostatic interactions within a structured hydrophobic core.

Bi-specific aptamers bind tumor antigens and immune proteins to form a molecular bridge, bypassing drug resistance in pancreatic cancer.

A demineralized bone matrix supplement delivers osteoinductive growth factors to induce bone cell proliferation and regeneration.

Transdermal microneedles replace oral dosing to eliminate rapid clearance fluctuations and stabilize serum T3 concentrations.

Direct compression of high drug load matrix minitablets achieves controlled release without complex polymeric coating steps.

Synthetic steroidal lactones with specific substituents enhance anticancer efficacy while reducing cardiovascular toxicity.

Iodine-doped polymer filaments provide targeted occlusion and controlled drug release while minimizing unintended flow blockage in vascular sites.

Purified Bombyx mori silk peptide fiber combines with refined Buglossoides arvensis seed oil to improve memory and cognitive performance.

Macrocyclic compounds remodel tumor vasculature and suppress cancer-associated fibroblasts through targeted structural design.

A hollow nasal implant assembly uses magnetic particles at its distal end to concentrate drug substances within the nasal cavity.

A three-step topical treatment uses a peel, foam, and barrier cream to boost dermal hyaluronic acid levels.

Lyophilized docetaxel conjugate powder adjusts pH to 4.5-5.5 for solubility, eliminating surfactant-induced adverse reactions and hemolytic side effects.

Antisense miR-21 oligonucleotides inhibit miR-21 to restore hMSH2 and overcome 5-fluorouracil resistance.

Inhalation bypasses hepatic first-pass metabolism and peripheral degradation, preserving drug stability.

A celecoxib nanoemulsion formulation delivers rapid analgesic action through optimized oil-in-water dispersion.

Compounds bind the AGR2 active site to disrupt disulfide bonding and reduce oncogenic protein production in breast and pancreatic cancers.

Allosteric isoindolinone inhibitors overcome T790M and C797S resistance by binding distal sites.

CRM1 inhibitors address treatment resistance by reducing seizure severity while minimizing side effects from conventional antiepileptic drugs.

Merges STING agonists with dual-specific antibodies blocking PD-L1 and PD-L2 to overcome tumor immune suppression.

An oral pharmaceutical composition binds active ingredients to an ion exchanger, impeding rapid absorption to prevent overingestion.

Taurolidine releases active moieties to destroy Candida auris blood-borne pathogens, addressing multidrug resistance and high mortality rates.

Optimized excipient combinations enable stable 100-210 mg/mL nimotuzumab solutions, eliminating hyaluronidase requirements for subcutaneous injection.

Rimonabant blocks cannabinoid receptors to increase motor excitability, resolving fatigue and spasticity trade-offs.

Attaching phytochemicals to nutrients leverages metabolic pathways to resolve low delivery efficiency and non-specific transport mechanisms.

Small molecule agonists activate EphA2 receptors to disrupt pro-oncogenic Akt-EphA2 crosstalk and reactivate tumor suppressor functions.

Therapeutic dsRNA increases exercise tolerance by 25% via parameter-based stratification, resolving ineffective conventional treatment outcomes.

Segmented ligand-drug conjugates achieve controlled release of therapeutic agents, improving tumor inhibition while reducing systemic toxicity.

Water-based self-emulsifying extraction isolates oleocanthal from olive oil, reducing solvent consumption and improving yield compared to traditional methods.

Selective depolymerization removes anticoagulant activity from heparin, enabling anti-metastatic treatment of cancer with reduced bleeding risk.

Carbazole carboxamide compounds inhibit Bruton's tyrosine kinase while maintaining selectivity over Jak2 kinase to treat autoimmune diseases.